Why the approval of Eli Lilly’s tirzepatide for diabetes will lead to blockbuster sales

On Friday, Eli Lilly (LLY) won approval of Mounjaro (tirzepatide), a novel once-weekly injectable medicine for type 2 diabetes.

What do you think?

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

5th annual ‘Walk to end Lupus” event returns to El Dorado

Lori Harvey Dragged By Twitter After Explaining Her Diet & Exercise Regimen